Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    166
    ...
ATC Name B/G Ingredients Dosage Form Price
P01AB01 FLAGYL B Metronidazole - 250mg 250mg Tablet, film coated 176,043 L.L
R05X DULSANA MILD B Menthol - 0.125mg/5ml, Citric acid - 10mg/5ml, Sodium citrate - 20mg/5ml, Ammonium chloride - 50mg/5ml, Ephedrine HCl - 1.8mg/5ml, Carbinoxamine maleate - 1mg/5ml Syrup 216,295 L.L
G03DA04 UTROGESTAN B Progesterone micronised natural - 200mg 200mg Capsule 587,259 L.L
H05BA01 MIACALCIC B Calcitonin (salmon synthetic) - 100IU/ml 100IU/ml Injectable solution 1,720,118 L.L
L01XX24 ONCASPAR B Pegaspargase - 750U/ml 750U/ml Injectable powder for solution 172,758,585 L.L
N05AX16 REXULTI B Brexpiprazole - 1mg 1mg Tablet, film coated 13,433,051 L.L
V03AE01 CALCIUM RESONIUM B Calcium Polystyrene Sulphonate - 15g 15g Powder 2,053,391 L.L
D04AA13 FENISTIL B Dimethindene maleate - 1mg/g 1mg/g Gel 196,201 L.L
H05BA01 MIACALCIC 200 UI/ACTUATION B Calcitonin (salmon synthetic) - 200IU/actuation 200IU/actuation Solution 5,399,559 L.L
M09AX01 HYALGAN B Hyaluronic acid (sodium) - 20mg/2ml 20mg/2ml Injectable solution 3,407,985 L.L
N05BA01 VALIUM B Diazepam - 5mg 5mg Tablet, scored 200,233 L.L
L01CX01 YONDELIS B Trabectedin - 1mg 1mg Injectable powder for solution 97,129,719 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution 38,083,434 L.L
M09AX10 EVRYSDI B Risdiplam - 0.75mg/ml 0.75mg/ml Powder 865,644,067 L.L
G03DA04 CRINONE B Progesterone - 8% 8% Gel 4,734,357 L.L
V03AE02 RENVELA B Sevelamer - 800mg 800mg Tablet, film coated 8,386,876 L.L
A03FA03 MOTILIUM B Domperidone - 10mg 10mg Tablet 353,431 L.L
G03DA04 ENDOMETRIN B Progesterone - 100mg 100mg Tablet 2,776,379 L.L
N01AB07 SUPRANE (DESFLURANE, USP) B Desflurane - Inhalation 9,371,654 L.L
A10BB12 AMARYL B Glimepiride - 3mg 3mg Tablet 392,402 L.L
D04AB01 XYLOCAINE B Lidocaine - 10mg/spray dose 100mg/ml Spray 667,890 L.L
G03DA04 PROGESTOGEL B Progesterone - 1% 1% Gel 542,912 L.L
N01AB08 SEVOFLURANE B Sevoflurane - Inhalation 12,327,290 L.L
G03DA04 PROGESTOGEL B Progesterone - 1% 1% Gel 542,912 L.L
L01DB01 CAELYX B Doxorubicin HCl pegylated liposomes - 20mg/10ml 20mg/10ml Injectable concentrated solution 33,495,068 L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg 10mg Tablet 12,966,030 L.L
N05BA08 LEXOTANIL B Bromazepam - 3mg 3mg Tablet, scored 413,903 L.L
D04AB01 VERSATIS B Lidocaine - 5% 5% Patch 13,085,712 L.L
J01DH03 INVANZ B Ertapenem - 1g 1g Injectable concentrated powder for solution 3,785,604 L.L
L01DB02 CERUBIDINE B Daunorubicin (HCl) - 20mg 20mg Injectable powder for solution 10,943,137 L.L
    ...
    166
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025